More Than 80,000 EpiPens Recalled Overseas

March 22, 2017

More than 80,000 EpiPens for anaphylactic shock have been recalled in a number of countries overseas because they may fail to inject their potentially life-saving dose of epinephrine, according to Mylan, the company that markets the devices.

The recall applies to devices distributed in Australia, Europe, Japan, and New Zealand, Mylan told Medscape Medical News. The United States is not on the list.

Pressing the EpiPen into a person's thigh — the prescribed area for administration — causes a needle to penetrate skin and inject epinephrine into muscle. The recalled EpiPens may contain a defective part that "may result in the device failing to activate or requiring increased force to activate," Mylan said in a news release on March 20.

Mylan cited two confirmed reports of the device failing to deliver its dose. The patients in question received emergency treatment from alternative, functioning EpiPens, Reuters reported today.

EpiPens are made by Meridian Medical Technologies, a subsidiary of Pfizer.

Follow Robert Lowes on Twitter @LowesRobert


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: